[go: up one dir, main page]

SK10912000A3 - Farmaceuticky prijateľné soli a solváty (+)-(2s,3s)-2-(3-chlórfenyl)-3,5,5-trimetyl-2-morfolinolu, farmaceutický prostriedok s ich obsahom a ich použitie - Google Patents

Farmaceuticky prijateľné soli a solváty (+)-(2s,3s)-2-(3-chlórfenyl)-3,5,5-trimetyl-2-morfolinolu, farmaceutický prostriedok s ich obsahom a ich použitie Download PDF

Info

Publication number
SK10912000A3
SK10912000A3 SK1091-2000A SK10912000A SK10912000A3 SK 10912000 A3 SK10912000 A3 SK 10912000A3 SK 10912000 A SK10912000 A SK 10912000A SK 10912000 A3 SK10912000 A3 SK 10912000A3
Authority
SK
Slovakia
Prior art keywords
morpholinol
compound
chlorophenyl
trimethyl
formula
Prior art date
Application number
SK1091-2000A
Other languages
English (en)
Slovak (sk)
Inventor
Phillip Frederick Morgan
David Lee Musso
John Joseph Partridge
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9801230.5A external-priority patent/GB9801230D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of SK10912000A3 publication Critical patent/SK10912000A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK1091-2000A 1998-01-21 1999-01-20 Farmaceuticky prijateľné soli a solváty (+)-(2s,3s)-2-(3-chlórfenyl)-3,5,5-trimetyl-2-morfolinolu, farmaceutický prostriedok s ich obsahom a ich použitie SK10912000A3 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9801230.5A GB9801230D0 (en) 1998-01-21 1998-01-21 Pharmaceutically active morpholinol
US7218098P 1998-01-22 1998-01-22
PCT/US1999/001134 WO1999037305A1 (en) 1998-01-21 1999-01-20 Pharmaceutically active morpholinol

Publications (1)

Publication Number Publication Date
SK10912000A3 true SK10912000A3 (sk) 2001-04-09

Family

ID=26312986

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1091-2000A SK10912000A3 (sk) 1998-01-21 1999-01-20 Farmaceuticky prijateľné soli a solváty (+)-(2s,3s)-2-(3-chlórfenyl)-3,5,5-trimetyl-2-morfolinolu, farmaceutický prostriedok s ich obsahom a ich použitie

Country Status (30)

Country Link
US (2) US6274579B1 (xx)
EP (2) EP1047428B1 (xx)
JP (1) JP2002501025A (xx)
KR (1) KR100568063B1 (xx)
CN (2) CN1203858C (xx)
AP (1) AP1229A (xx)
AT (1) ATE365042T1 (xx)
AU (1) AU755536B2 (xx)
BR (1) BR9907203A (xx)
CA (1) CA2318268A1 (xx)
CY (1) CY1106828T1 (xx)
DE (1) DE69936335T2 (xx)
DK (1) DK1047428T3 (xx)
EA (1) EA002410B1 (xx)
EE (1) EE04452B1 (xx)
ES (1) ES2288012T3 (xx)
HR (2) HRP20051024A2 (xx)
HU (1) HUP0100900A3 (xx)
ID (1) ID26334A (xx)
IL (2) IL137346A0 (xx)
IS (1) IS2494B (xx)
NO (2) NO326878B1 (xx)
NZ (3) NZ529316A (xx)
PL (1) PL193622B1 (xx)
PT (1) PT1047428E (xx)
SG (1) SG115489A1 (xx)
SK (1) SK10912000A3 (xx)
TR (1) TR200002126T2 (xx)
WO (1) WO1999037305A1 (xx)
YU (1) YU67102A (xx)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098206B2 (en) * 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
WO1999038503A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmacological uses of optically pure (+)-bupropion
WO1999038504A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
US6855820B2 (en) 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
EP1220673A2 (en) * 1999-10-13 2002-07-10 Glaxo Group Limited Morpholinol derivatives for the treatment of obesity
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US7145649B2 (en) * 2000-12-21 2006-12-05 Brasscorp Limited Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing
US6979104B2 (en) 2001-12-31 2005-12-27 R.J. Doran & Co. LTD LED inspection lamp
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
JP4545584B2 (ja) * 2002-05-17 2010-09-15 デューク ユニバーシティ 肥満を治療するための方法
GB0219687D0 (en) * 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
US7384941B2 (en) * 2002-08-23 2008-06-10 Eli Lilly And Company 2-(phenoxymethyl)-and 2-(phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
MXPA05011557A (es) 2003-04-29 2006-03-09 Orexigen Therapeutics Inc Composiciones para afectar perdida de peso.
WO2005042503A1 (en) * 2003-10-27 2005-05-12 Smithkline Beecham Corporation Enzyme-catalyzed dynamic kinetic resolution process for preparing (+)-(2s, 3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, salts, and solvates thereof
GB0325055D0 (en) * 2003-10-27 2003-12-03 Smithkline Beecham Corp New process
GB0326148D0 (en) * 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
GB0327195D0 (en) * 2003-11-21 2003-12-24 Smithkline Beecham Corp Novel use
GB0327619D0 (en) * 2003-11-27 2003-12-31 Smithkline Beecham Corp New use
AU2005206139B2 (en) 2004-01-13 2009-02-26 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
BRPI0510593A (pt) * 2004-05-03 2007-11-20 Univ Duke composições para afetar a perda de peso
FI117283B (fi) 2005-02-04 2006-08-31 Kone Corp Hissijärjestelmä
EP2292220A3 (en) 2005-11-22 2012-01-04 Orexigen Therapeutics, Inc. Composition and methods for increasing insulin sensitivity
US7763612B2 (en) * 2006-01-03 2010-07-27 Algebra, Inc. Therapeutic amine-arylsulfonamide conjugate compounds
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
CN101588795A (zh) 2006-11-09 2009-11-25 奥雷西根治疗公司 包含中间快速溶解层的分层药物制剂
US20090075994A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched radafaxine
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
CA2758774C (en) 2009-04-15 2015-02-03 Research Triangle Institute Monoamine reuptake inhibitors
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
AU2011255456B2 (en) 2010-05-21 2017-01-19 Dignity Health Doing Business As St. Joseph's Hospital And Medical Center And Barrow Neurological Institute 1 - phenylmorpholine derivatives as hydroxybupropion analogues for treating drug dependence
JP2013526583A (ja) 2010-05-21 2013-06-24 リサーチ・トライアングル・インスティチュート フェニルモルホリンおよびその類似体
US9510405B2 (en) 2011-06-30 2016-11-29 Schneider Electric Industries Sas Dual power SMPS for a modular lighting system
CN102670617B (zh) * 2012-04-13 2013-03-20 湖南大学 布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用
KR20220042241A (ko) 2012-06-06 2022-04-04 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법
CN105949142B (zh) * 2016-05-21 2018-03-27 南华大学 具有抗抑郁活性的单一手性化合物及其制备方法和应用
RU2763728C1 (ru) * 2021-06-17 2021-12-30 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US170430A (en) * 1875-11-30 Improvement in furnaces for heating steel in tempering
GB8417170D0 (en) 1984-07-05 1984-08-08 Wellcome Found Heterocyclic pharmaceutical compounds
GB9108629D0 (en) 1991-04-23 1991-06-12 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use

Also Published As

Publication number Publication date
HRP20000494A2 (en) 2000-12-31
EP1047428A4 (en) 2001-12-19
TR200002126T2 (tr) 2000-12-21
NO20003721D0 (no) 2000-07-20
KR20010034285A (ko) 2001-04-25
DK1047428T3 (da) 2007-10-08
US20020019396A1 (en) 2002-02-14
PL342012A1 (en) 2001-05-07
DE69936335T2 (de) 2008-02-28
IS5568A (is) 2000-07-20
CN1528753A (zh) 2004-09-15
IL137346A0 (en) 2001-07-24
WO1999037305A1 (en) 1999-07-29
AP2000001869A0 (en) 2000-09-30
EA002410B1 (ru) 2002-04-25
DE69936335D1 (de) 2007-08-02
HUP0100900A3 (en) 2002-08-28
AU755536B2 (en) 2002-12-12
EE200000438A (et) 2001-12-17
CY1106828T1 (el) 2012-05-23
EP1047428B1 (en) 2007-06-20
CN1255389C (zh) 2006-05-10
NO20083529L (no) 2000-09-19
EP1047428A1 (en) 2000-11-02
KR100568063B1 (ko) 2006-04-07
HRP20000494B1 (en) 2009-02-28
SG115489A1 (en) 2005-10-28
CN1203858C (zh) 2005-06-01
CA2318268A1 (en) 1999-07-29
JP2002501025A (ja) 2002-01-15
HRP20051024A2 (hr) 2006-04-30
IS2494B (is) 2009-02-15
BR9907203A (pt) 2000-10-17
NZ529316A (en) 2004-05-28
YU67102A (sh) 2004-12-31
AP1229A (en) 2003-12-04
EA200000691A1 (ru) 2001-04-23
AU2328099A (en) 1999-08-09
NZ505809A (en) 2002-09-27
NO326878B1 (no) 2009-03-09
EE04452B1 (et) 2005-04-15
HUP0100900A2 (hu) 2002-05-29
ID26334A (id) 2000-12-14
US6391875B2 (en) 2002-05-21
NO20003721L (no) 2000-09-19
NZ520349A (en) 2004-02-27
ATE365042T1 (de) 2007-07-15
EP1829544A1 (en) 2007-09-05
IL161942A0 (en) 2005-11-20
CN1294513A (zh) 2001-05-09
PL193622B1 (pl) 2007-02-28
ES2288012T3 (es) 2007-12-16
PT1047428E (pt) 2007-09-07
US6274579B1 (en) 2001-08-14

Similar Documents

Publication Publication Date Title
SK10912000A3 (sk) Farmaceuticky prijateľné soli a solváty (+)-(2s,3s)-2-(3-chlórfenyl)-3,5,5-trimetyl-2-morfolinolu, farmaceutický prostriedok s ich obsahom a ich použitie
Robertson et al. The absolute configurations and pharmacological activities of the optical isomers of fluoxetine, a selective serotonin-uptake inhibitor
FR2611707A1 (fr) Nouveau carbamate de phenyle, sa preparation et son utilisation comme medicament
US20230150936A1 (en) Analogs of n,n,n-trimethyl-4-phosphoryloxytryptamine
SK9002001A3 (en) 5ht1 antagonists for antidepressant therapy
US6855820B2 (en) Pharmaceutically active morpholinol
US6734213B2 (en) Pharmaceutically active morpholinol
US6998400B2 (en) Pharmaceutically active morpholinol
US7098206B2 (en) Pharmaceutically active morpholinol
AU2002315922B2 (en) Pharmaceutically active morpholinol
CZ20002690A3 (cs) Farmaceuticky přijatelné soli a solváty (+)- (2S,3S)-2-(3-chlorfenyl)-3,5,5-trimethyl-2- morfolinolu a farmaceutický prostředek
EP1761262B1 (en) Marine compounds with calcium channel blocking properties for the treatment of cognitive or neurodegenerative diseases
HK1107521A (en) Pharmaceutically active morpholinol
MXPA00007127A (en) Pharmaceutically active morpholinol
KR20040023653A (ko) 제약상 활성인 모르폴리놀